Indian vaccine developer Bharat Biotech is considering an initial public offering that may raise more than $500 million (₹4,551 crore), Bloomberg reported. Deliberations are ongoing and details of the deal including the size and timing may change, the report added. Notably, Bharat Biotech developed India's first indigenous COVID-19 vaccine. Its products include vaccines for hepatitis B.